Investments
196Portfolio Exits
50Funds
2Partners & Customers
1
Want to inform investors similar to Casdin Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Casdin Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Casdin Capital in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing Casdin Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Casdin Capital in 5 CB Insights research briefs, most recently on Sep 19, 2022.

Latest Casdin Capital News
May 3, 2023
Orbital Therapeutics – a company that is focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease – announced the successful closing of $270 million Series A financing. The Series A funding round was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors. Orbital Therapeutics is aiming to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement. And the company is building a first-in-kind RNA platform that integrates both established and emerging RNA technologies and delivery mechanisms. This platform was designed to extend the durability of Orbital’s novel RNA therapeutics, while also expanding their delivery to a wide range of cell types and tissues. Along with financing, Orbital announced the expansion of its leadership team with the appointments of Niru Subramanian as chief operating officer and Jonathan Piazza as the chief financial officer, who join Gilles Besin, Ph.D., chief scientific officer, and Dr. Ciaramella on the company’s executive leadership team. Subramanian brings 25 years of business and corporate development experience, including building new strategies and capabilities for high-growth organizations, leading multifunctional teams, managing partnerships and M&A transactions, and directing portfolio planning, alliance management, finance and operations. And Subramanian most recently served as chief operating officer at Rheos Medicines, and prior to that, was senior vice president, corporate development & business planning at Agios Pharmaceuticals, where she led several key initiatives including the $2 billion sale of Agios’ oncology business in December 2020. Earlier, Subramanian held several roles at Novartis Vaccines, including as vice president, head of Influenza Global Programs and at Novartis as vice president, Vaccines Business transition lead following the divestment of the business unit. Earlier in her career, she worked at The Boston Consulting Group in their healthcare practice area advising large and small biopharma companies on a variety of strategic and operational issues. Subramanian received a BS in computer science and engineering from the University of Pennsylvania and an MBA from the Harvard Business School. Piazza is a seasoned biotech executive and finance professional with more than 20 years of experience in biotech, healthcare investment banking, finance, and large pharma roles. He most recently served as CFO of Silverback Therapeutics and helped orchestrate its IPO, and later its reverse merger with ARS Pharma. As a healthcare banker at Goldman Sachs, Barclays Capital, and Lehman Brothers, Piazza has advised on approximately $100 billion in biopharma and life sciences financing and strategic transactions across both large and small companies. Previously, Piazza was a financial advisor at Smith Barney (now Morgan Stanley Smith Barney), and prior to that, he worked in engineering, development, and international marketing disciplines at Abbott Laboratories across multiple divisions of the company. Piazza earned a BS in chemical engineering from The Ohio State University and an MBA from the Haas School of Business at the University of California at Berkeley. KEY QUOTES: “In recent years, we have only just started to see the expansive potential RNA-based therapeutics may offer to the future of medicine and how we treat disease. Since our founding, we have been diligently focused on advancing our platform of RNA technologies to elucidate the most promising opportunities with our initial programs so we may reach patients as efficiently as possible. We are thrilled to have the backing of such an exceptional group of investors, whose support further enables the growth of our organization and the meaningful expansion of our platform and portfolio.” — Giuseppe Ciaramella, Ph.D., Orbital co-founder and CEO “Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Orbital was founded and has been built to be that special company. We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines.” — Kristina Burow, managing partner at ARCH Venture Partners, co-founder and board director of Orbital “Key to our long-term success is having a team that not only brings experience, but also passion and drive for the work we are doing. Niru has an extensive background in driving corporate strategy and portfolio development for successful biotech and pharmaceutical companies, which is complemented by Jonathan’s successful history of leading financial organizations within the industry and guiding several strategic transactions while at top investment banks. Their collective expertise and dedication to create a company that can advance important new medicines for patients makes them ideal additions to our team, and they already have made tremendous early contributions to our company’s growth and capital raise. We are thrilled to have them on board.” — Dr. Ciaramella
Casdin Capital Investments
196 Investments
Casdin Capital has made 196 investments. Their latest investment was in Orbital Therapeutics as part of their Series A on April 4, 2023.

Casdin Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/26/2023 | Series A | Orbital Therapeutics | $270M | Yes | Abu Dhabi Growth Fund, Agent Capital, Alexandria Venture Investments, Andreessen Horowitz, ARCH Venture Partners, Casdin Capital, Heritage Medical Systems, iGlobe Partners, Invus Group, Lingotto, Moore Strategic Ventures, Newpath Partners, Redmile Group, Rellim Capital Management, and Undisclosed Investors | 11 |
4/12/2023 | Series A | Function Oncology | $28M | Yes | 3 | |
3/22/2023 | Series B | Flare Therapeutics | $123M | No | 6 | |
3/16/2023 | Series C - III | |||||
3/1/2023 | Series B |
Date | 4/26/2023 | 4/12/2023 | 3/22/2023 | 3/16/2023 | 3/1/2023 |
---|---|---|---|---|---|
Round | Series A | Series A | Series B | Series C - III | Series B |
Company | Orbital Therapeutics | Function Oncology | Flare Therapeutics | ||
Amount | $270M | $28M | $123M | ||
New? | Yes | Yes | No | ||
Co-Investors | Abu Dhabi Growth Fund, Agent Capital, Alexandria Venture Investments, Andreessen Horowitz, ARCH Venture Partners, Casdin Capital, Heritage Medical Systems, iGlobe Partners, Invus Group, Lingotto, Moore Strategic Ventures, Newpath Partners, Redmile Group, Rellim Capital Management, and Undisclosed Investors | ||||
Sources | 11 | 3 | 6 |
Casdin Capital Portfolio Exits
50 Portfolio Exits
Casdin Capital has 50 portfolio exits. Their latest portfolio exit was Structure Therapeutics on February 03, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/3/2023 | IPO | Public | 23 | ||
10/20/2022 | IPO | Public | 18 | ||
7/21/2022 | IPO | Public | 2 | ||
Date | 2/3/2023 | 10/20/2022 | 7/21/2022 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 23 | 18 | 2 |
Casdin Capital Fund History
2 Fund Histories
Casdin Capital has 2 funds, including Casdin Private Growth Equity Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/9/2020 | Casdin Private Growth Equity Fund | $179M | 1 | ||
2/28/2018 | Casdin Venture Opportunities Fund |
Closing Date | 11/9/2020 | 2/28/2018 |
---|---|---|
Fund | Casdin Private Growth Equity Fund | Casdin Venture Opportunities Fund |
Fund Type | ||
Status | ||
Amount | $179M | |
Sources | 1 |
Casdin Capital Partners & Customers
1 Partners and customers
Casdin Capital has 1 strategic partners and customers. Casdin Capital recently partnered with Codexis on November 11, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/24/2020 | Partner | United States | Codexis And Casdin Capital Launch SynBio Innovation Accelerator To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis , Inc. , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 , including Codexis , Inc. ' expectations regarding its partnership with Casdin Capital and its investment in Arzeda Corp. . | 3 |
Date | 11/24/2020 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | Codexis And Casdin Capital Launch SynBio Innovation Accelerator To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis , Inc. , they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 , including Codexis , Inc. ' expectations regarding its partnership with Casdin Capital and its investment in Arzeda Corp. . |
Sources | 3 |
Casdin Capital Team
1 Team Member
Casdin Capital has 1 team member, including current Founder, Chief Investment Officer, Eli Casdin.
Name | Work History | Title | Status |
---|---|---|---|
Eli Casdin | AllianceBernstein, Bear Stearns, and Cooper Hill Partners | Founder, Chief Investment Officer | Current |
Name | Eli Casdin |
---|---|
Work History | AllianceBernstein, Bear Stearns, and Cooper Hill Partners |
Title | Founder, Chief Investment Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.